List view / Grid view


Mundipharma launches Remsima®▼ (infliximab), a new-generation value-based monoclonal antibody, in six European markets

25 February 2015 | By Mundipharma

Mundipharma International Limited’s network of independent associated companies are launching Remsima® (infliximab) this month in Germany, Italy, UK, Netherlands, Belgium and Luxembourg following expiry of the relevant patents and Supplementary Protection Certificates, having secured distribution rights from Celltrion Healthcare Hungary Kft for Remsima in these markets...

Cancer risk linked to DNA ‘wormholes’

19 February 2015 | By The Institute of Cancer Research

Single-letter genetic variations within parts of the genome once dismissed as ‘junk DNA’ can increase cancer risk through wormhole-like effects on far-off genes, new research shows...